Beckham Gumbin Ventures (BGV), a commercial real estate investor and developer, is beginning construction on brand new R&D laboratory spec suites and amenities at Ballenger Bio (321 Ballenger Center Drive) in Frederick, Maryland. Ballenger Bio will offer several 3,000 to 7,000 SF R&D laboratory spec suites, with the ability to combine up to 37,000 SF of contiguous space on a single floor. Building such spec labs will allow for growing biotech companies to focus on their business as opposed to construction costs and timelines.
Virginia Beach is seeking to build a bio cluster in the heart of everything Virginia Beach has to offer. The cluster reached an important milestone, recently opening a brand new accelerator lab constructed and managed by BioHealth Capital Region (BHCR) stalwart Facility Logix. VABeachBio and its partners see this new lab as a sign of great things to come.
Matan Companies announces today leasing has begun at Progress Labs at Riverside I in Frederick, Maryland. Receiving its site plan approval on March 9, the 215,000 square feet of biomanufacturing-ready space will include a 96,000 square foot existing building as well as a 119,000 square foot expansion building, which is slated to break ground in May 2021 and is expected to be fully complete by Spring 2022.
The Matan Cos. will add biotech manufacturing and research space to one of its existing office campuses in Germantown to meet the surge in demand from local life sciences firms.
A Virginia Beach biotech accelerator program announced more than five years ago as a way to attract a booming, high-salary industry to the area has completed lab construction and is finally looking for tenants.
CRB, a leading design-build firm specializing in tech and life science facilities, recently announced the launch of SlateXpace, a groundbreaking design-build solution for life science facilities. SlateXpace is a modular, multi-modal facility solution for the development and manufacture of Advanced Therapy Medicinal Products (ATMP) that offers life science organizations unprecedented construction speed, development flexibility, manufacturing adaptability, and budget control.
New Alliance Launches to Make it Easier for Biopharma Companies to Reshore Manufacturing Operations in US
Andrew Davis is Vice President at Scheer Partners and helps run the scientific real estate practice. Andrew lives in Maryland but assists scientific companies identify, negotiate, and build space in the Biohealth Capital Region, Philadelphia / Greater PA, and Massachusetts.
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability June 18, 2020 Company acquires property adjacent to its Canton, Massachusetts live viral [….]
Rock Creek Property Group Breaks Ground on BIO at 700 QO October 30, 2019 Rock Creek Property Group (Rock Creek) officially broke ground on its redevelopment of 700 Quince Orchard [….]